Skip to main content
IBRX
NASDAQ Life Sciences

ImmunityBio's Q1 Revenue Jumps 168% to Record $44M, Cash Nears $381M

Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$6.94
Mkt Cap
$7.176B
52W Low
$1.83
52W High
$12.43
52W Position info
279% above low
Off High info
44% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

IBRX has more than doubled off its 52-week low of $1.83.

Summary

ImmunityBio announced strong preliminary Q1 2026 results, reporting a record $44 million in net product revenue, representing a substantial 168% year-over-year increase. This performance continues the positive commercial trajectory for ANKTIVA, following the 700% revenue growth highlighted in the company's recent 2025 annual report. The company also reported a healthy cash and marketable securities balance of approximately $381 million at quarter-end. This significant revenue growth and solid cash position are highly material, indicating strong commercial execution and financial stability. Investors will monitor the upcoming full Q1 10-Q for detailed financials and further updates on ANKTIVA's market penetration and pipeline advancements, including the planned supplemental BLA submission.

At the time of this announcement, IBRX was trading at $6.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2B. The 52-week trading range was $1.83 to $12.43. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.


Price Chart

Share this article

Copied!

IBRX - Latest Insights

IBRX
Nov 09, 2026, 7:52 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $7.59
Real-time Price: $6.08 info
Change: -$1.51 (-20%) info
Market Cap: $6.404B info
IBRX
Nov 09, 2026, 7:39 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.09
Real-time Price: $6.08 info
Change: -$2.01 (-25%) info
Market Cap: $6.404B info
IBRX
Nov 09, 2026, 7:30 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $8.84
Real-time Price: $6.08 info
Change: -$2.76 (-31%) info
Market Cap: $6.404B info
IBRX
Nov 09, 2026, 6:30 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $8.76
Real-time Price: $6.08 info
Change: -$2.68 (-31%) info
Market Cap: $6.404B info
IBRX
Oct 16, 2026, 11:49 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $9.42
Real-time Price: $6.08 info
Change: -$3.34 (-35%) info
Market Cap: $6.404B info